GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » ARYx Therapeutics Inc (OTCPK:ARYX) » Definitions » Price-to-Free-Cash-Flow

ARYx Therapeutics (ARYx Therapeutics) Price-to-Free-Cash-Flow : N/A (As of May. 05, 2024)


View and export this data going back to 2007. Start your Free Trial

What is ARYx Therapeutics Price-to-Free-Cash-Flow?

As of today (2024-05-05), ARYx Therapeutics's share price is $0.0005. ARYx Therapeutics's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Sep. 2010 was $-0.67. Hence, ARYx Therapeutics's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for ARYx Therapeutics's Price-to-Free-Cash-Flow or its related term are showing as below:

ARYX's Price-to-Free-Cash-Flow is not ranked *
in the Drug Manufacturers industry.
Industry Median: 22.61
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

ARYx Therapeutics's Free Cash Flow per Share for the three months ended in Sep. 2010 was $-0.12. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $-0.67.


ARYx Therapeutics Price-to-Free-Cash-Flow Historical Data

The historical data trend for ARYx Therapeutics's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ARYx Therapeutics Price-to-Free-Cash-Flow Chart

ARYx Therapeutics Annual Data
Trend Dec03 Dec04 Dec05 Dec06 Dec07 Dec08 Dec09
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial - - - - -

ARYx Therapeutics Quarterly Data
Dec05 Mar06 Jun06 Sep06 Dec06 Mar07 Jun07 Sep07 Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of ARYx Therapeutics's Price-to-Free-Cash-Flow

For the Drug Manufacturers - Specialty & Generic subindustry, ARYx Therapeutics's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ARYx Therapeutics's Price-to-Free-Cash-Flow Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, ARYx Therapeutics's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where ARYx Therapeutics's Price-to-Free-Cash-Flow falls into.



ARYx Therapeutics Price-to-Free-Cash-Flow Calculation

ARYx Therapeutics's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=0.0005/-0.667
=N/A

ARYx Therapeutics's Share Price of today is $0.0005.
ARYx Therapeutics's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Sep. 2010 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.67.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

ARYx Therapeutics  (OTCPK:ARYX) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


ARYx Therapeutics Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of ARYx Therapeutics's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


ARYx Therapeutics (ARYx Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
6300 Dumbarton Circle, Fremont, CA, USA, 94555
ARYx Therapeutics Inc is a biopharmaceutical company focused on developing a portfolio of internally discovered product candidates designed to eliminate known safety issues associated with well-established, commercially successful drugs.
Executives
Newhall Charles W Iii 10 percent owner 1119 ST PAUL ST, BALTIMORE MD 21202
C Richard Kramlich 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Ryan D Drant 10 percent owner 1119 ST PAUL STREET, BALTIMORE MD 21202
Krishna Kittu Kolluri 10 percent owner
New Enterprise Associates 12, Limited Partnership 10 percent owner 1119 ST. PAUL STREET, BALTIMORE MD 21202
Nea Partners 12, Limited Partnership 10 percent owner 1119 ST. PAUL STREET, BALTIMORE MD 21202
Nea 12 Gp, Llc 10 percent owner 1119 ST. PAUL STREET, BALTIMORE MD 21202
Mark W Perry 10 percent owner
Patrick J Kerins 10 percent owner
Forest Baskett 10 percent owner
Growth Equity Opportunities Fund, Llc 10 percent owner 1119 ST. PAUL STREET, BALTIMORE MD 21202
Peter J Barris 10 percent owner 1119 ST PAUL STREET, BALTIMORE MD 21202
M James Barrett 10 percent owner 1119 ST PAUL STREET, BALTIMORE MD 21202
Scott D Sandell 10 percent owner
Nicholas Galakatos 10 percent owner THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH FLOOR, BOSTON MA 02116

ARYx Therapeutics (ARYx Therapeutics) Headlines

No Headlines